10.21147/j.issn.1000-9604.2021.01.11
Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label,phase Ⅰ dose escalation and dose expansion trial
33
2021-04-14(万方平台首次上网日期,不代表论文的发表时间)
共12页
103-114